Literature DB >> 25537684

'Partial' competition of heterobivalent ligand binding may be mistaken for allosteric interactions: a comparison of different target interaction models.

Georges Vauquelin1, David Hall, Steven J Charlton.   

Abstract

BACKGROUND AND
PURPOSE: Non-competitive drugs that confer allosteric modulation of orthosteric ligand binding are of increasing interest as therapeutic agents. Sought-after advantages include a ceiling level to drug effect and greater receptor-subtype selectivity. It is thus important to determine the mode of interaction of newly identified receptor ligands early in the drug discovery process and binding studies with labelled orthosteric ligands constitute a traditional approach for this. According to the general allosteric ternary complex model, allosteric ligands that exhibit negative cooperativity may generate distinctive 'competition' curves: they will not reach baseline levels and their nadir will increase in par with the orthosteric ligand concentration. This behaviour is often considered a key hallmark of allosteric interactions. EXPERIMENTAL APPROACH: The present study is based on differential equation-based simulations. KEY
RESULTS: The differential equation-based simulations revealed that the same 'competition binding' pattern was also obtained when a monovalent ligand binds to one of the target sites of a heterobivalent ligand, even if this process is exempt of allosteric interactions. This pattern was not strictly reciprocal when the binding of each of the ligands was recorded. The prominence of this phenomenon may vary from one heterobivalent ligand to another and we suggest that this phenomenon may take place with ligands that have been proposed to bind according to 'two-domain' and 'charnière' models. CONCLUSIONS AND IMPLICATIONS: The present findings indicate a familiar experimental situation where bivalency may give rise to observations that could inadvertently be interpreted as allosteric binding. Yet, both mechanisms could be differentiated based on alternative experiments and structural considerations.
© 2014 The British Pharmacological Society.

Mesh:

Substances:

Year:  2015        PMID: 25537684      PMCID: PMC4403095          DOI: 10.1111/bph.13053

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  55 in total

1.  Effect of bivalent interaction upon apparent antibody affinity: experimental confirmation of theory using fluorescence photobleaching and implications for antibody binding assays.

Authors:  E N Kaufman; R K Jain
Journal:  Cancer Res       Date:  1992-08-01       Impact factor: 12.701

Review 2.  Structural basis of allosteric ligand-receptor interactions in the insulin/relaxin peptide family: implications for other receptor tyrosine kinases and G-protein-coupled receptors.

Authors:  Pierre De Meyts; Lisbeth Gauguin; Angela Manegold Svendsen; Mazen Sarhan; Louise Knudsen; Jane Nøhr; Vladislav V Kiselyov
Journal:  Ann N Y Acad Sci       Date:  2009-04       Impact factor: 5.691

3.  Simplified models for heterobivalent ligand binding: when are they applicable and which are the factors that affect their target residence time.

Authors:  Georges Vauquelin
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-06-28       Impact factor: 3.000

Review 4.  New protein engineering approaches to multivalent and bispecific antibody fragments.

Authors:  A Plückthun; P Pack
Journal:  Immunotechnology       Date:  1997-06

Review 5.  Exploring avidity: understanding the potential gains in functional affinity and target residence time of bivalent and heterobivalent ligands.

Authors:  Georges Vauquelin; Steven J Charlton
Journal:  Br J Pharmacol       Date:  2013-04       Impact factor: 8.739

6.  A thermodynamic approach to problems of drug antagonism I. The "Charnière theory".

Authors: 
Journal:  Eur J Pharmacol       Date:  1969       Impact factor: 4.432

7.  Approximating the effects of diffusion on reversible reactions at the cell surface: ligand-receptor kinetics.

Authors:  B Goldstein; M Dembo
Journal:  Biophys J       Date:  1995-04       Impact factor: 4.033

8.  A novel multivalent ligand that bridges the allosteric and orthosteric binding sites of the M2 muscarinic receptor.

Authors:  Tod Steinfeld; Mathai Mammen; Jacqueline A M Smith; Richard D Wilson; Jeffrey R Jasper
Journal:  Mol Pharmacol       Date:  2007-05-03       Impact factor: 4.436

9.  Bitopic ligands: all-in-one orthosteric and allosteric.

Authors:  Maud Kamal; Ralf Jockers
Journal:  F1000 Biol Rep       Date:  2009-10-14

10.  Activation and allosteric modulation of a muscarinic acetylcholine receptor.

Authors:  Andrew C Kruse; Aaron M Ring; Aashish Manglik; Jianxin Hu; Kelly Hu; Katrin Eitel; Harald Hübner; Els Pardon; Celine Valant; Patrick M Sexton; Arthur Christopoulos; Christian C Felder; Peter Gmeiner; Jan Steyaert; William I Weis; K Christopher Garcia; Jürgen Wess; Brian K Kobilka
Journal:  Nature       Date:  2013-11-20       Impact factor: 49.962

View more
  6 in total

Review 1.  On the different experimental manifestations of two-state 'induced-fit' binding of drugs to their cellular targets.

Authors:  Georges Vauquelin; Isabelle Van Liefde; David C Swinney
Journal:  Br J Pharmacol       Date:  2016-03-15       Impact factor: 8.739

Review 2.  G Protein-Coupled Receptors in Asthma Therapy: Pharmacology and Drug Action.

Authors:  Stacy Gelhaus Wendell; Hao Fan; Cheng Zhang
Journal:  Pharmacol Rev       Date:  2020-01       Impact factor: 25.468

3.  Distinct in vivo target occupancy by bivalent- and induced-fit-like binding drugs.

Authors:  Georges Vauquelin
Journal:  Br J Pharmacol       Date:  2017-10-18       Impact factor: 8.739

Review 4.  What Do Structures Tell Us About Chemokine Receptor Function and Antagonism?

Authors:  Irina Kufareva; Martin Gustavsson; Yi Zheng; Bryan S Stephens; Tracy M Handel
Journal:  Annu Rev Biophys       Date:  2017-05-22       Impact factor: 12.981

5.  Bitopic fluorescent antagonists of the A2A adenosine receptor based on pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine functionalized congeners.

Authors:  Romain Duroux; Antonella Ciancetta; Philip Mannes; Jinha Yu; Shireesha Boyapati; Elizabeth Gizewski; Said Yous; Francisco Ciruela; John A Auchampach; Zhan-Guo Gao; Kenneth A Jacobson
Journal:  Medchemcomm       Date:  2017-06-22       Impact factor: 3.597

6.  Divalent ligand-monovalent molecule binding.

Authors:  Mathijs Janssen; Harald Stenmark; Andreas Carlson
Journal:  Soft Matter       Date:  2021-06-02       Impact factor: 3.679

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.